A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Infusion (GT201) in Combination with PD-1 Inhibitor for Advanced Head and Neck Tumors
Latest Information Update: 21 Feb 2025
At a glance
- Drugs GT-201 (Primary) ; Programmed cell death 1 receptor antagonists (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors GRIT Biotechnology
- 07 Feb 2025 Planned number of patients changed from 32 to 12.
- 25 Jul 2024 Status changed from not yet recruiting to recruiting.
- 20 Mar 2024 Planned End Date changed from 19 Jan 2027 to 30 Apr 2027.